A Study to Evaluate Splenectomy on Debridement for Acute Necrotizing Pancreatitis With Pancreatic Sinistral Portal Hypertension

NCT07080697 · tracked via the Priya Life Science China tracker

Sponsor

Zhejiang University

Phase

Not applicable

Started

2025-07-30

Last updated

2025-07-23

Condition(s) studied

Acute Necrotizing PancreatitisPortal Hypertension

Investigational drug(s) / intervention(s)

SplenectomyControl

Splenectomy: Open Debridement combined with distal pancreatectomy and total splenectomy

Control: Open Debridement alone

Study summary

This study is a prospective, single-center, randomized controlled trial focusing on patients with acute necrotizing pancreatitis (ANP) complicated by pancreatic sinistral portal hypertension (PSPH). The study aims to study the impact of total splenectomy on the debridement efficacy, perioperative recovery, and prognosis of patients with ANP complicated by PSPH.

Eligibility

Sex

ALL

Min age

18 Years

Max age

75 Years

Healthy volunteers

Inclusion Criteria: 1. Age between 18 and 75 years. 2. Acute necrotic pancreatitis complicated by pancreatic sinistral portal hypertension. 3. Patients undergoing open debridement for infected pancreatic necrosis Exclusion Criteria: 1. Patients with pre-existing heart, lung, liver, kidney, or other organ failure prior to acute pancreatitis (AP). 2. Patients with pre-existing conditions such as cirrhosis that may lead to portal hypertension prior to AP. 3. Patients with pre-existing hematological diseases prior to AP. 4. Patients undergoing laparoscopic or nephroscopic debridement.

Primary outcome measure(s)

Length of hospital stay after debridement — From enrollment of the first subject to completion of follow-up of the last subject (up to 5 years)
The total length of hospital stay after debridement, including readmissions.
Degree of pancreatic sinistral portal hypertension — From enrollment of the first subject to completion of follow-up of the last subject (up to 5 years)
The degree of pancreatic sinistral portal hypertension after intervention

Trial sites (1)

Facility	City	Region	Status
First Affiliated Hospital, Zhejiang University School of Medicine	Hangzhou	Zhejiang	Recruiting

More Zhejiang University trials in China

HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients Recruiting

LISH Trial for the Hepatic Flexure and Proximal Transverse Colon Cancer Recruiting

Transarterial Neoadjuvant Chemotherapy vs.Traditional Intravenous Chemotherapy For Locally Advanced Gastric Cancer With SOX+PD-1 Recruiting

A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly Patients After Urological Surgery Starting soon

Hepatic Artery Transfusion of NKG2D CAR-NK Cells Followed by Intravenous Infusion of NKG2D CAR-T Cells to Treat Patients With Advanced Solid Tumors With Liver Metastases Who Have Failed Standard Treatments: a Phase I Exploratory Clinical Trial Recruiting

Other trials for the same condition

EUS Guided Portal-systemic Pressure Gradient Measurement Recruiting

Underdilated VCX-TIPS Versus EVL Plus NSBB for Secondary Prophylaxis of Variceal Bleeding in Cirrhosis Starting soon

Improve the Strategies of Endoscopic and Interventional Treatment of Gastroesophageal Hemorrhage in Portal Hypertension Recruiting

3D-MRE for Assessing Cirrhosis, Advanced Chronic Liver Disease and Portal Hypertension Recruiting

The Effect of Laparoscopic Splenectomy and Azygoportal Disconnection on Liver Reserve Function for Cirrhosis Patients Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07080697 on ClinicalTrials.gov ↗ ← All trials in China